Description: Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Home Page: ateapharma.com
AVIR Technical Analysis
125 Summer Street
Boston,
MA
02110
United States
Phone:
857 284 8891
Officers
| Name | Title |
|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & Pres |
| Ms. Andrea J. Corcoran J.D. | CFO, Exec. VP of Legal & Sec. |
| Mr. John F. Vavricka | Chief Commercial Officer |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Devel. Officer |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer |
| Mr. Wayne Foster CPA, CPA | Exec. VP of Fin. & Chief Accounting Officer |
| Ms. Jonae R. Barnes | Sr. VP of Investor Relations & Corp. Communications |
| Mr. Ariyapadi N. Krishnaraj | VP of Marketing |
| Mr. Adel Moussa Ph.D. | Exec. VP of Chemistry |
| Mr. Xiao-Jian Zhou Ph.D. | Exec. VP of Early Stage Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 12.3158 |
| Price-to-Book MRQ: | 0.5513 |
| Price-to-Sales TTM: | 1.9026 |
| IPO Date: | 2020-10-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 68 |